Elisabetta Venturelli

List of Publications by Year
in descending order

42 papers	2,225 citations	257101 24 h-index	253896 43 g-index
43 all docs	43 docs citations	43 times ranked	3248 citing authors

#	Article	IF	Citations
1	Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. Clinical Breast Cancer, 2021, 21, e168-e176.	1.1	13
2	Adherence to Dietary Recommendations after One Year of Intervention in Breast Cancer Women: The DIANA-5 Trial. Nutrients, 2021, 13, 2990.	1.7	18
3	A Mediterranean Dietary Intervention in Female Carriers of BRCA Mutations: Results from an Italian Prospective Randomized Controlled Trial. Cancers, 2020, 12, 3732.	1.7	14
4	Monitoring Vitamin B12 in Women Treated with Metformin for Primary Prevention of Breast Cancer and Age-Related Chronic Diseases. Nutrients, 2019, 11, 1020.	1.7	5
5	A management system for randomized clinical trials: A novel way to supply medication. PLoS ONE, 2019, 14, e0212475.	1.1	2
6	Serum levels of testosterone and SHBG in association with body mass index improve the predictive capability of consolidate tumor biomarkers in pre- and postmenopausal breast cancer patients. Japanese Journal of Clinical Oncology, 2018, 48, 308-316.	0.6	3
7	Effect of aerobic exercise intervention on markers of insulin resistance in breast cancer women. European Journal of Cancer Care, 2018, 27, e12617.	0.7	30
8	Adherence to Mediterranean Diet and Metabolic Syndrome in BRCA Mutation Carriers. Integrative Cancer Therapies, 2018, 17, 153-160.	0.8	28
9	A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers. Cancers, 2018, 10, 309.	1.7	18
10	Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. BMC Cancer, 2018, 18, 651.	1.1	16
11	A randomized controlled trial of Mediterranean diet and metformin to prevent age-related diseases in people with metabolic syndrome. Tumori, 2018, 104, 137-142.	0.6	12
12	Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients. International Journal of Cancer, 2016, 138, 237-244.	2.3	34
13	Androgen Receptor CAG Repeat Length and Estrogen Receptor Status in Postmenopausal Breast Cancer Prognosis. International Journal of Biological Markers, 2015, 30, 418-424.	0.7	3
14	Metabolic syndrome and breast cancer prognosis. Breast Cancer Research and Treatment, 2014, 147, 159-165.	1.1	114
15	Metformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer. Clinical Breast Cancer, 2013, 13, 433-438.	1.1	48
16	Serum Fatty Acids and Risk of Cutaneous Melanoma: A Population-Based Case-Control Study. Dermatology Research and Practice, 2013, 2013, 1-7.	0.3	11
17	Lifestyle and Breast Cancer Recurrences: The DIANA-5 Trial. Tumori, 2012, 98, 1-18.	0.6	88
18	Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer, 2012, 12, 599.	1.1	16

#	Article	IF	Citations
19	Effect of Different Doses of Metformin on Serum Testosterone and Insulin in Non-Diabetic Women With Breast Cancer: A Randomized Study. Clinical Breast Cancer, 2012, 12, 175-182.	1.1	56
20	Potential role of HER2â€overexpressing exosomes in countering trastuzumabâ€based therapy. Journal of Cellular Physiology, 2012, 227, 658-667.	2.0	410
21	Lifestyle and breast cancer recurrences: the DIANA-5 trial. Tumori, 2012, 98, 1-18.	0.6	48
22	Circulating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional Study. International Journal of Biological Markers, 2011, 26, 241-246.	0.7	8
23	Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Familial Cancer, 2011, 10, 521-528.	0.9	27
24	Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 729-737.	1.1	60
25	Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2942-2948.	1.1	21
26	Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2008, 100, 898-905.	3.0	94
27	Serum Insulin-Like Growth Factor-I and Platelet-Derived Growth Factor as Biomarkers of Breast Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1719-1722.	1.1	49
28	Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 33-42.	1.1	29
29	Re: Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer Among Premenopausal Women. Journal of the National Cancer Institute, 2007, 99, 408-409.	3.0	2
30	Plasma Testosterone and Prognosis of Postmenopausal Breast Cancer Patients. Journal of Clinical Oncology, 2007, 25, 2685-2690.	0.8	58
31	Metabolic syndrome as a prognostic factor for breast cancer recurrences. International Journal of Cancer, 2006, 119, 236-238.	2.3	208
32	Serum testosterone levels and breast cancer recurrence. International Journal of Cancer, 2005, 113, 499-502.	2.3	84
33	Endogenous sex hormones and subsequent breast cancer in premenopausal women. International Journal of Cancer, 2004, 112, 312-318.	2.3	128
34	Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas, 2004, 47, 11-20.	1.0	58
35	Effects of dietary intervention on IGF-I and IGF-binding proteins, and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomised Trial. European Journal of Clinical Nutrition, 2003, 57, 1079-1088.	1.3	102
36	The effects of a soy rich diet on serum lipids: the Menfis randomized trial. Maturitas, 2002, 41, 97-104.	1.0	42

#	Article	IF	Citations
37	Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Maturitas, 2002, 42, 295-300.	1.0	100
38	Methods for urinary testosterone analysis. Biomedical Applications, 1995, 671, 363-380.	1.7	42
39	Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 541-546.	1.2	98
40	Testosterone levels as a marker of prognosis to Goserelin treatment in metastatic breast cancer. European Journal of Cancer, 1994, 30, 1629-1631.	1.3	5
41	Urinary testosterone as a marker of risk of recurrence in operable breast cancer. Breast Cancer Research and Treatment, 1993, 26, 1-6.	1.1	13
42	Urinary testosterone measurement by gas chromatography after solid-phase extraction and high-performance liquid chromatography. Biomedical Applications, 1992, 582, 7-12.	1.7	8